Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

2.

MafA-deficient and beta cell-specific MafK-overexpressing hybrid transgenic mice develop human-like severe diabetic nephropathy.

Shimohata H, Yoh K, Fujita A, Morito N, Ojima M, Tanaka H, Hirayama K, Kobayashi M, Kudo T, Yamagata K, Takahashi S.

Biochem Biophys Res Commun. 2009 Nov 13;389(2):235-40. doi: 10.1016/j.bbrc.2009.08.124. Epub 2009 Aug 26.

PMID:
19715672
3.

Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.

Yoshida S, Hashimoto T, Kihara M, Imai N, Yasuzaki H, Nomura K, Kiuchi Y, Tamura K, Ishigami T, Hirawa N, Toya Y, Kitamura H, Umemura S.

Nephron Exp Nephrol. 2009;111(1):e20-30. doi: 10.1159/000178764. Epub 2008 Dec 2.

PMID:
19052474
4.

Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.

Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y.

J Nephrol. 2003 Nov-Dec;16(6):841-9.

PMID:
14736011
5.

[Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].

Shao JQ, Iwashita N, Du H, Wang YY, Zhao M, Wang J, Watada H, Kawamori R.

Zhonghua Nei Ke Za Zhi. 2007 Apr;46(4):306-10. Chinese.

PMID:
17637271
6.

Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice.

Naito Y, Uchiyama K, Aoi W, Hasegawa G, Nakamura N, Yoshida N, Maoka T, Takahashi J, Yoshikawa T.

Biofactors. 2004;20(1):49-59.

PMID:
15096660
7.

Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.

Haneda M, Kikkawa R, Sakai H, Kawamori R; Candesartan in Diabetic Nephropathy Study Group.

Diabetes Res Clin Pract. 2004 Oct;66(1):87-95.

PMID:
15364166
8.

Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.

Sen S, Kanter M, Ustundag S, Aktas C, Dogutan H, Yalcin O.

Ren Fail. 2008;30(10):1023-33. doi: 10.1080/08860220802495248. Erratum in: Ren Fail. 2009;31(2):180. Saniye, Sen [corrected to Sen, Saniye]; Mehmet, Kanter [corrected to Kanter, Mehmet]; Sedat, Ustundag [corrected to Ustundag, Sedat]; Cevat, Aktas [corrected to Aktas, Cevat]; Omer, Yalcin [corrected to Yalcin, Omer].

PMID:
19016156
9.

Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.

Mima A, Arai H, Matsubara T, Abe H, Nagai K, Tamura Y, Torikoshi K, Araki M, Kanamori H, Takahashi T, Tominaga T, Matsuura M, Iehara N, Fukatsu A, Kita T, Doi T.

Diabetes. 2008 Jun;57(6):1712-22. doi: 10.2337/db07-1726. Epub 2008 Feb 19.

10.

Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.

Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y.

Nephrol Dial Transplant. 2004 Dec;19(12):3012-20.

PMID:
15574998
11.

The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.

Nagisa Y, Shintani A, Nakagawa S.

Diabetologia. 2001 Jul;44(7):883-8.

PMID:
11508274
12.

Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.

Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M.

Hypertens Res. 2003 Jun;26(6):453-8.

13.

Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.

Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M.

Horm Metab Res. 2004 Jul;36(7):458-64.

PMID:
15305228
15.

Candesartan: nephroprotective effects and treatment of diabetic nephropathy.

Mimran A, Alfaro V.

Drugs Today (Barc). 2003 Jun;39(6):439-50. Review.

PMID:
12944996
16.

Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes.

Kanetsuna Y, Hirano K, Nagata M, Gannon MA, Takahashi K, Harris RC, Breyer MD, Takahashi T.

Am J Physiol Renal Physiol. 2006 Dec;291(6):F1315-22. Epub 2006 May 16.

17.

Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.

Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, Imura Y.

Kidney Int. 1999 Sep;56(3):898-909.

18.

Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.

Zhou G, Cheung AK, Liu X, Huang Y.

Clin Sci (Lond). 2014 May;126(10):707-20. doi: 10.1042/CS20130223.

PMID:
24195695
19.

Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.

Ohtomo S, Ito M, Izuhara Y, Van Ypersele De Strihou C, Miyata T.

Nephrology (Carlton). 2008 Dec;13(6):517-21. doi: 10.1111/j.1440-1797.2008.00929.x. Epub 2008 Mar 17.

PMID:
18363646
20.

The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.

Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, Jandeleit-Dahm KA.

Am J Physiol Renal Physiol. 2010 Sep;299(3):F528-35. doi: 10.1152/ajprenal.00127.2010. Epub 2010 Jun 16.

Supplemental Content

Support Center